← Issue №17/ week of Oct 25, 2026/Pancreas/Biliary

Metabolic dysfunctions in pancreatic ductal adenocarcinoma: Pathogenic mechanisms and therapeutic implications.

From GI Signals issue №17: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Pancreas/Biliary review · Oct 20, 2026 · Pancreatology · IF 3.0

Metabolic dysfunctions in pancreatic ductal adenocarcinoma: Pathogenic mechanisms and therapeutic implications.

Basic sciencebasic sciencetranslationalpancreatic cancerbiomarker
Clinical takeawayNo clinical action yet: preclinical findings in PDAC models suggest potential for metabolic modulators, but human evidence is inconclusive.
What it foundStatins and metformin show antitumor effects in preclinical PDAC models, but clinical trial data on survival benefits remain inconsistent.
ContextChallenges current understanding of PDAC treatment by highlighting metabolic dysfunctions as drivers of chemoresistance and proposing repurposed metabolic modulators.
Emergingsuggested applicable standard· American Diabetes Association Professional Practice Committee, "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026," Diabetes Care 2026;49(Supplement_1):S132-S149

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Manage diabetes in GI/hepatology patients by individualizing the A1c target to the population, in cirrhosis, A1c is unreliable because altered red blood cell turnover typically underestimates glycemia, so set glycemic goals using blood glucose monitoring and/or CGM rather than a fixed A1c cutoff, and in diabetic gastroparesis individualize the target rather than applying a universal cutoff; ≤7% pre-bariatric, <6.5% pre-conception, while screening all T2DM for MASLD with FIB-4, screening T1DM for concurrent celiac disease, and screening for diabetic gastroparesis when chronic nausea, early satiety, or postprandial fullness are present. Evaluate new-onset DM after age 50 without obesity for a pancreatic cancer differential, and coordinate peri-procedural medication holds and multidisciplinary endocrinology involvement.

American Diabetes Association Professional Practice Committee, "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026," Diabetes Care 2026;49(Supplement_1):S132-S149 · reviewed 2026-07-23 ↗
Rodrigues R … Xavier CPR · Pancreatology : Official Journal of the International Association of Pancreatology (IAP) .. [et Al.] · IF 3.0 · PubMed ↗Permalink
← Read the whole of issue №17 Every paper GI Signals surfaces gets a page like this one. All issues